Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 54 (1976), S. 235-237 
    ISSN: 1432-1440
    Keywords: DNA-dependent RNA-polymerase B ; Functional properties and regulation ; Leukemia ; DNS-abhängige RNS-Polymerase B ; Funktionelle Differenzierung und Regulation ; Leukaemie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Es werden die spezifischen Aktivitäten von zwei funktionell unterschiedlichen Fraktionen der α-Amanitin-inhibierbaren DNS-abhängigen RNS-Polymerase in Zellkernen normaler menschlicher Lymphocyten (NL) sowie von Lymphocyten bei chronischer lymphatischer Leukämie (CLL) bestimmt. Die Aktivität der „freien“ RNS-Polymerase bei CLL beträgt 0,133 gegenüber 0,209 pMol (3H)-UMP/106 Zellen in normalen Lymphocyten. Die Aktivitäten der „gebundenen“ Enzyme liegen bei 0,139 (CLL) bzw. 0,132 pMol (3H)-UMP/106 Zellen (NL). Durch 400 ng/ml Rifamycin AF/013 wird das „freie“ Enzym in NL und CLL völlig inhibiiert, während das „gebundene“ Enzym noch 70% seiner Aktivität aufweist. Da „freie“ Enzym in CLL-Lymphocyten wird durch 1,0 ng/ml α-Amanitin zu 50% inhibitiert, während dieses Enzym in NL sowie die „gebundenen“ Enzyme in NL und CLL zu mehr als 90% inaktiviert werden.
    Notes: Summary Specific activities are determined of two functional fractions of α-amanitin sensitive DNA-dependent RNA polymerases in nuclei from human normal and chronic lymphocytic leukemia lymphocytes. Specific activity of “free” RNA polymerase in CLL corresponds to 0.133 pmoles (3H)-UMP/106 cells as compared to 0.209 in normals. Activities of the “engaged” enzymes are 0.139 in CLL and 0.132 in normals. “Free” enzymes in NL and CLL are completely inhibited by 400 ng/ml Rifamycin AF/013, while the “engaged” enzymes exhibit 70% of their original activity. 1.0 ng/ml α-amanitin suppress 50% of the activity of the “free” enzyme in CLL. The “free” enzyme in NL and the “engaged” enzymes in NL and CLL do not show any residual activity in the presence of 1.0 ng/ml α-amanitin.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 51 (1973), S. 730-734 
    ISSN: 1432-1440
    Keywords: Leukocytes ; Leukemia ; RNA-polymerase ; RNA-metabolism ; Leukocyten ; Leukämie ; RNS-Polymerase ; RNS-Stoffwechsel
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Lymphocyten und Leukocyten (Lymphocyten + Granulocyten) werden aus 10–40 ml heparinisiertem Venenblut isoliert, homogenisiert und 15 min bei 1000 g zentrifugiert. In dem aus Zellkernen und Kerntrümmern bestehenden Sediment lassen sich nach Resuspension ca. 70% der DNA-abhängigen RNS-Polymerase-Aktivität des Homogenats nachweisen. Die Reaktion ist von zugesetzter DNS und der Gegenwart aller vier Ribonucleosid-Triphosphate abhängig. Bei chronisch lymphatischer Leukämie, chronisch myeloischer Leukämie und Morbus Hodgkin findet sich unter diesen Bedingungen eine höhere spezifische Aktivität der DNS-abhängigen RNS-Polymerase als bei Normalpersonen.
    Notes: Summary Lymphocytes and leukocytes (lymphocytes + granulocytes), isolated from 10–40 ml of heparinized venous blood, are homogenized, and centrifuged for 15 min at 1000 g. The resuspended pellet, consisting of nuclei and nuclear debris, exhibits ca. 70% of the DNA-depenent RNA polymerase activity of the homogenate. The reaction depends on added DNA template and the presence of all four ribonucleoside triphosphates. In chronic lymphatic leukaemia, chronic myelocytic leukemia, and Hodgkin's disease, the activity of the DNA-dependent RNA polymerase is higher than in normal controls.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Annals of hematology 70 (1995), S. 15-17 
    ISSN: 1432-0584
    Keywords: Key words Fas antigen ; Apoptosis ; Leukemia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary  The antigen defined by the monoclonal antibody anti-Fas can mediate apoptosis, is associated with the receptor for tumor necrosis factor, and is expressed on a limited number of human tissues. In this study we analyzed the expression of Fas on primary human leukemic cells and on mononuclear cells from other hematologic disorders. A total of 95 samples of blood or bone marrow were studied by indirect immunofluorescence. These samples included the normal controls, 47 cases of acute myelogenous leukemia (AML), 11 cases of acute lymphoblastic leukemia (ALL), 21 cases of leukemic lymphoma, seven cases of chronic myelogenous leukemia (CML), five cases of plasma cell leukemia or multiple myeloma, and five cases of myelodysplastic or myeloproliferative syndromes. Normal controls were negative without exception. Among AML, 13/47 cases (28%) were positive; among ALL, 1/11 cases (9%) was positive; among leukemic lymphomas, 3/21 cases (14%) were positive. In a case of plasma cell leukemia which strongly expressed the Fas antigen, we demonstrated that the antibody mediates cell lysis, which was synergistically enhanced by the addition of rabbit complement. In patients with AML, Fas positivity had no obvious clinical relevance. Taken together, our results show that approximately 30% of cases of AML and occasionally other leukemias express the Fas antigens, whereas normal controls are negative in our test system. These findings may be useful in the treatment of refractory leukemias or may permit the purging of autologous transplants.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Springer
    Annals of hematology 70 (1995), S. 15-17 
    ISSN: 1432-0584
    Keywords: Fas antigen ; Apoptosis ; Leukemia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The antigen defined by the monoclonal antibody anti-Fas can mediate apoptosis, is associated with the receptor for tumor necrosis factor, and is expressed on a limited number of human tissues. In this study we analyzed the expression of Fas on primary human leukemic cells and on mononuclear cells from other hematologic disorders. A total of 95 samples of blood or bone marrow were studied by indirect immunofluorescence. These samples included the normal controls, 47 cases of acute myelogenous leukemia (AML), 11 cases of acute lymphoblastic leukemia (ALL), 21 cases of leukemic lymphoma, seven cases of chronic myelogenous leukemia (CML), five cases of plasma cell leukemia or multiple myeloma, and five cases of myelodysplastic or myeloproliferative syndromes. Normal controls were negative without exception. Among AML, 13/47 cases (28%) were positive; among ALL, 1/11 cases (9%) was positive; among leukemic lymphomas, 3/21 cases (14%) were positive. In a case of plasma cell leukemia which strongly expressed the Fas antigen, we demonstrated that the antibody mediates cell lysis, which was synergistically enhanced by the addition of rabbit complement. In patients with AML, Fas positivity had no obvious clinical relevance. Taken together, our results show that approximately 30% of cases of AML and occasionally other leukemias express the Fas antigens, whereas normal controls are negative in our test system. These findings may be useful in the treatment of refractory leukemias or may permit the purging of autologous transplants.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...